TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
The maximum duration of participation is approximately 9 months. Patients will complete a screening period of up to 21 days. Following screening, eligible patients will be randomly assigned to 1 of 3 treatment sequences. Each patient will undergo 2 14-week treatment periods for a total of 28 weeks (Treatment Period 1 and Treatment Period 2). After completing the 2 treatment periods, patients will enter a 1-month follow-up period.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental/Placebo (Type: EXPERIMENTAL): Subjects will be randomized to receive C1 Esterase Inhibitor in the 1st Treatment period and then switch to Placebo in the 2nd treatment period.
- Placebo/Experimental (Type: EXPERIMENTAL): Subjects will be randomized to receive a placebo treatment in the 1st Treatment period and then switch to receive C1 Esterase Inhibitor in the 2nd treatment period.
- Experimental/ Experimental (Type: EXPERIMENTAL): Subjects will be randomized and receive C1 Esterase Inhibitor in both 1st as well as the 2nd treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have at least one chronic non-healing Wagner Grade 1 or Grade 2 plantar neuropathic diabetic ulcer between 1.0-6.0 cm2 on the midfoot or forefoot, including the toes but excluding the heel.~* ABI greater than 0.7 for neuroischemic or greater than 0.8 for neuropathic DU~* TcPO2 greater than 40 mm Hg or great toe systolic pressure greater than 50 mmHg~* Type I or Type II diabetes under metabolic control~* Female subjects must have a negative pregnancy test and be willing to use acceptable method of birth control for the duration of the study~Exclusion Criteria:~* Exposure to any investigational product within the last 30 days, or have known hypersensitivity to any of the study medication components~* Chronic renal insufficiency and/or chronic liver dysfunction~* Resting blood pressure (at the time of the initial visit of the Screening Period) which exceeds 160 systolic and/or 90 diastolic mmHg on 3 consecutive readings at least 15 minutes apart~* Malignancy of any kind~* Receiving hemodialysis or CAPD~* Current history of drug abuse, and/or known to be HIV positive~* Prior radiation therapy of the foot under study~* Current use of corticosteroids (within past 8 weeks), immunosuppressants (within past 8 weeks), or use of a biologic agent to include growth factors and skin equivalents (Regranex, Apligraft, or Dermagraft) in the past 90 days~* Ulcer is deemed clinically infected and requires topical antimicrobials or agents known to affect wound healing, or the subject has been taking systemic antibiotics for more than 7 days for any reason~* Sickle-cell anemia, Raynaud's or other peripheral vascular disease~* Wagner Grade 3 or higher DU, deep abscess or infection of the joint or tendon, or gangrene or osteomyelitis~* An EKG with a marked baseline prolongation of QT/QTc interval

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Vehicle Control (Type: PLACEBO_COMPARATOR): control placebo vehicle gel
- 0.03% DSC127 (Type: ACTIVE_COMPARATOR): 0.03 % DSC127 in Vehicle Control
- 0.01% DSC127 (Type: ACTIVE_COMPARATOR): 0.01% DSC127 in Vehicle Control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Enrollment in Biomarkers to Guide Directional DBS for Parkinson's Disease (ClinicalTrials.gov Identifier: NCT03353688)~* Diagnosis of Parkinson's disease with and without dystonia~Exclusion Criteria:~* Not enrolled in Biomarkers to Guide Directional DBS for Parkinson's Disease (ClinicalTrials.gov Identifier: NCT03353688)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Dystonia Severity Assessment (Type: EXPERIMENTAL): We will measure the effects of DBS on dystonia by assessing changes in the Burke-Fahn-Marsden Dystonia Rating Scale at 2, 4, 6, and 12 months after surgery to implant the Boston Scientific Vercise PC IPG with directional DBS lead versus preoperative baseline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 49, inclusive at the time of enrolment~* in good health as determined by the outcome of medical history, physical examination screening/baseline labs and clinical judgment of the investigator~* Male~* Must have received polio vaccinations with OPV according to the Polish National Immunization Program as a child based on vaccination cards or information given by subjects during interview with investigator~* Preferred: number (and date) of polio vaccinations known~* Willingness and ability to adhere to the study regimen~* Having a signed informed consent form~Exclusion Criteria:~* IPV or OPV booster dose after the age of 12 years~* Positive for HIV, Hepatitis B or Hepatitis C~* Known or suspected allergy against any of the vaccine components~* History of unusual or severe reactions to any previous vaccination~* Known or suspected disease or use of medication that may influence the immune system~* Known or suspected immune deficiency~* Systemic treatment with corticosteroids within one month before screening~* Administration of plasma (including immunoglobulins) or blood products three months prior to the study~* Blood donation within one month before screening~* Any vaccination within three months before screening and during the study until the last visit~* History of any neurological disorder including epilepsy or febrile seizures~* Evidence of excessive alcohol use or drug use~* Any infectious disease at the time of screening and/or inclusion~* Participation in another clinical trial within three months before screening~* Abnormal pre-treatment laboratory parameters which are clinically relevant according to the investigator~* Bleeding disorders or the usage of anticoagulants

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Sabin-IPV (Type: EXPERIMENTAL): Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, and 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose
- Adjuvanted Sabin-IPV (Type: EXPERIMENTAL): Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, and 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose, adjuvanted with 0.5 mg aluminium hydroxide
- IPV (Type: ACTIVE_COMPARATOR): Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained from the subject.~* Aged 18 years or above at screening.~* In good general health~* Subject available for the study duration~* For female subjects (of child bearing potential) a negative pregnancy tests at Screening and Day 0.~Exclusion Criteria:~* A history of vaccination against or infection with JE.~* Known or suspected immunodeficiency, use of immunosuppressive or antineoplastic drugs.~* History of thymoma, thymic surgery (removal) or myasthenia gravis.~* Clinically significant abnormalities on laboratory assessment~* Anaphylaxis or other serious adverse reactions characterised by urticaria or angioedema to foods, Hymenoptera (bee family) stings, or drugs including vaccines).~* Transfusion of blood or treatment with any blood product, including intramuscular or intravenous serum globulin within six months of the Screening Visit or up to Day 30.~* Administration of another vaccine or antiviral within 30 days preceding the Screening visit or up to Day 30.~* Physical examination indicating any clinically significant medical condition.~* Oral temperature \>38°C (100.4°F) or acute illness within 3 days prior to inoculation.~* Intention to travel out of the area for an extended period that may affect the subjects ability to attend clinic visits prior to the study visit up to Day 30.~* Seropositive to hepatitis C virus (HCV) or HIV or positive for Hepatitis B Surface Antigen.~* Lactation or intended pregnancy in female subjects.~* Excessive alcohol consumption, drug abuse, significant psychiatric illness.~* A known or suspected physiological or structural condition that compromises the integrity of the blood-brain barrier (e.g. cerebrovascular disease, multiple sclerosis, trauma, infection, inflammation of the brain or meninges).~* Participation in another clinical study within 30 days of the screening visit for this study.~* Employee of the study site, Sponsor or Clinical Research Organization (CRO) involved with the management of the study.~* Any other reasons, which in the investigator's opinion, makes the subject unsuitable to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): All subjects received a single injection of placebo on Day 0.
- ChimeriVax™ JE 4 log10 PFU Vaccine (Type: EXPERIMENTAL): All participants received a single injection of ChimeriVax™ JE 4 log10 Plaque-forming unit (PFU) Vaccine on Day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HCV RNA ≥ 10,000 IU/mL at screening~* HCV genotype 1 or 4~* HIV-1 infection~* Cirrhosis determination, a fibroscan or liver biopsy may be required~* Screening laboratory values within defined thresholds~* Use of protocol specified method(s) of contraception if female of childbearing potential or sexually active male~Exclusion Criteria:~* Clinically-significant illness (other than HCV or HIV) or any other major medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol~* Current or prior history of clinical hepatic decompensation, hepatocellular carcinoma (HCC), or other malignancy (with the exception of certain resolved skin cancers)~* Hepatitis B virus (HBV) infection~* Pregnant or nursing female~* Chronic use of systemically administered immunosuppressive agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF 12 Weeks (Type: EXPERIMENTAL): LDV/SOF for 12 weeks
- Retreatment Substudy (Type: EXPERIMENTAL): LDV/SOF plus RBV for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated patients with MCL aged 65 years or more, or \<65 years if not eligible for intensive treatments including/not including autologous transplantation.~* MCL patients of any age who relapse/progress or are resistant after one line of chemotherapy.~* CD20+ .~* Karnofsky score of at least 70%~* Adequate renal function (Creatinine clearance \>40 mL/min), with preserved diuresis.~* Adequate liver function: alanine aminotransferase (ALT)/aspartate aminotransferase (AST) \<2.5 x upper limit of normal (ULN) value, total bilirubin \<2 mg/dL, unless directly attributable to the patient's tumor.~* Negative serum pregnancy test 1 week prior to treatment both for pre-menopausal women and for women who are \<2 years after onset of menopause.~* Hepatitis B core antibody (HBcAb) positive patients may be enrolled if correct antiviral prophylaxis is administered at least 2 weeks before initiating protocol treatment.~* Written informed consent.~Exclusion Criteria:~* Prior treatment with Bendamustine.~* Refractoriness to Rituximab, defined as progressive disease during a previous cycle including this drug, or relapse within 6 months to any previous cycle including Rituximab.~* Previous Rituximab infusion-related severe reactions.~* Human immunodeficiency virus (HIV) positive.~* Medical conditions or organ injuries that could interfere with administration of therapy.~* Active bacterial, viral, or fungal infection requiring systemic therapy.~* Seizure disorders requiring anticonvulsant therapy.~* Severe chronic obstructive pulmonary disease with hypoxaemia.~* History of severe cardiac disease: New York Heart Association (NYHA) functional class III-IV, myocardial infarction within 6 months, ventricular tachyarrhythmias, dilatative cardiomyopathy, or unstable angina.~* Uncontrolled diabetes mellitus.~* Active secondary malignancy.~* Known hypersensitivity or anaphylactic reactions to murine antibodies and proteins (for patients treated with Rituximab), to Bendamustine or mannitol.~* Fertile men and women of childbearing potential unless surgically sterile or using adequate measures of contraception.~* Major surgery within 4 weeks of study Day 1.~* HBsAg+ and HCV+ patients~* Any co-existing medical or psychological condition that would preclude participation in the study or compromise the patient's ability to give informed consent, or that may affect the interpretation of the results, or render the patient at high risk from treatment complications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Branched-chain Amino Acids (BCAA) to Muscle Cramps in Patients With Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Muscle cramp ≥ 1 time per week~* Confirmed cirrhotic status (radiologic finding compatible with cirrhosis or liver stiffness measurement ≥ 12.5 kPa by transient elastography method or pathological confirm of cirrhosis)~Exclusion Criteria:~* Allergy to BCAA~* Overt hepatic encephalopathy~* Hepatorenal syndrome~* Severe renal insufficiency; eGFR \< 30~* Heart failure~* Peripheral arterial disease~* Active malignancies beyond hepatocellular carcinoma~* Heavy alcohol drinking (\> 21g/day for men and \>14g/day for women)~* Pregnancy or lactation~* Current use of BCAA within 3 months~* Recent adding or titrating diuretics within 4 weeks~* On current medications for muscle cramp relief such as vitamin E, taurine, carnitine, narcotic pain medications, baclofen, methocarbamol, other muscle relaxers, NSAIDs, or other antispastic agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- BCAA group (Type: ACTIVE_COMPARATOR): 12.45 grams of branched-chain amino acids orally per day before bedtime for 12 weeks.
- Placebo group (Type: PLACEBO_COMPARATOR): 12.45 grams of placebo (Maltodextrin) orally per day before bedtime for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults with ADHD~Exclusion Criteria:~* Other Axis I Psychiatric Disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be at least 18 years of age.~* Males and females with a documented diagnosis of UC at least 4 months prior to entry into the study.~* Subjects with moderately to severely active UC based on Mayo score criteria.~* Subjects must have failed or be intolerant of at least one of the following treatments for UC:~  * Corticosteroids (oral or intravenous).~ * Azathioprine or 6 mercaptopurine (6 MP).~ * Anti TNF therapy.~Exclusion Criteria:~* Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease.~* Subjects with disease limited to distal 15 cm.~* Subjects without previous treatment for UC (ie, treatment naïve).~* Subjects displaying clinical signs of fulminant colitis or toxic megacolon.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tofacitinib 10 mg BID (Type: EXPERIMENTAL): None
- Placebo BID (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Positive Airway Pressure and Acetazolamide to Treat Sleep Apnea Syndrome Patients at Altitude

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obstructive sleep apnea syndrome, successfully on CPAP therapy~* Residence at low altitude (\< 800 m)~* Obstructive apnea/hypopnea index \>20/h and a complaint of excessive daytime sleepiness before introduction of CPAP therapy~* \> 15 oxygen desaturations/h (\> 3% dips) during an ambulatory nocturnal pulse oximetry performed at the end of a 4-night period without CPAP~Exclusion Criteria:~* Sleep disorders other than OSA~* More than mild cardiovascular disease, unstable cardiovascular disease~* Any lung disease, pulmonary hypertension~* Chronic rhinitis~* Treatment with drugs that affect respiratory center drive (benzodiazepines or other sedatives or sleep inducing drugs, morphine or codeine derivates), stimulants (modafinil, methylphenidate, theophylline)~* Internal, neurologic or psychiatric disease that interfere with sleep quality~* Previous intolerance to moderate or low altitude (\< 2600 m)~* Exposure to altitudes \> 1500m for \> 1 day within the last 4 weeks before the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- acetazolamide (Type: EXPERIMENTAL): combination of acetazolamide and nocturnal continuous positive airway pressure ventilation
- placebo capsules (Type: PLACEBO_COMPARATOR): combination of placebo and nocturnal continuous positive airway pressure ventilation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DS-5565 Phase III Study for Renal Impairment in Japanese Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At screening, creatinine clearance (using the Cockcroft-Gault equation): 15-59 mL/min~* At screening, a pain scale of ≥ 40 mm~* Type 1 or type 2 diabetes mellitus at screening (for patients with diabetic peripheral neuropathic pain DPNP only)-. Painful distal symmetric polyneuropathy (for patients with DPNP only)~* post-herpetic neuralgia PHN defined as pain present for more than 3 months after herpes zoster skin rash at screening (for patients with PHN only)~Exclusion Criteria:~* HbA1c (National Glycohemoglobin Standardization Program) \> 10.0% (for patients with DPNP only)~* Previous use of neurolytic block (for patients with PHN only)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DS-5565 group (Type: EXPERIMENTAL): DS-5565 15 mg (for moderate renal impairment) or 7.5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete